DE60042021D1 - Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors - Google Patents

Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors

Info

Publication number
DE60042021D1
DE60042021D1 DE60042021T DE60042021T DE60042021D1 DE 60042021 D1 DE60042021 D1 DE 60042021D1 DE 60042021 T DE60042021 T DE 60042021T DE 60042021 T DE60042021 T DE 60042021T DE 60042021 D1 DE60042021 D1 DE 60042021D1
Authority
DE
Germany
Prior art keywords
hgf
factor
growth factor
met receptor
nuclear acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60042021T
Other languages
English (en)
Inventor
Judy Ruckman
Larry Gold
Andrew Stephens
Nebojsa Janjic
Ross Rabin
Michael Lochrie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/364,539 external-priority patent/US6344321B1/en
Priority claimed from US09/364,543 external-priority patent/US6331394B1/en
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of DE60042021D1 publication Critical patent/DE60042021D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE60042021T 1999-07-29 2000-07-24 Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors Expired - Lifetime DE60042021D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/364,539 US6344321B1 (en) 1990-06-11 1999-07-29 Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US09/364,543 US6331394B1 (en) 1991-06-10 1999-07-29 Nucleic acid ligands to integrins
PCT/US2000/020139 WO2001009159A1 (en) 1990-06-11 2000-07-24 Nucleic acid ligands to hepatocyte growth factor/scatter factor (hgf/sf) or its receptor c-met and to integrins

Publications (1)

Publication Number Publication Date
DE60042021D1 true DE60042021D1 (de) 2009-05-28

Family

ID=40577369

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60042021T Expired - Lifetime DE60042021D1 (de) 1999-07-29 2000-07-24 Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors

Country Status (3)

Country Link
US (3) US20030049644A1 (de)
AT (1) ATE428719T1 (de)
DE (1) DE60042021D1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8389710B2 (en) * 2004-02-27 2013-03-05 Operational Technologies Corporation Therapeutic nucleic acid-3′-conjugates
FR2867784B1 (fr) * 2004-03-17 2006-06-09 Commissariat Energie Atomique Aptameres selectionnes a partir de cellules vivantes tumorales et leurs applications
EP1918372A4 (de) * 2005-07-05 2009-08-12 Ribomic Inc Zur bindung an immunglobulin g fähige nukleinsäure und verwendung davon
ES2369739T3 (es) * 2006-03-20 2011-12-05 Seikagaku Corporation Agente terapéutico para la artritis reumatoide.
JP4698559B2 (ja) * 2006-11-24 2011-06-08 Ｎｅｃソフト株式会社 ウサギ由来のＩｇＧ抗体に結合性を有する核酸分子
EP2101807B1 (de) 2006-12-19 2016-05-25 Genentech, Inc. Vegf-spezifische antagonisten für adjuvante und neoadjuvante therapie sowie zur tumorbehandlung im frühstadium
US20110092452A1 (en) * 2008-03-05 2011-04-21 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating pancreatic cancer
CN102137939A (zh) * 2008-08-29 2011-07-27 霍夫曼-拉罗奇有限公司 不依赖vegf的肿瘤的诊断和治疗
AR077595A1 (es) 2009-07-27 2011-09-07 Genentech Inc Tratamientos de combinacion
US8236570B2 (en) * 2009-11-03 2012-08-07 Infoscitex Methods for identifying nucleic acid ligands
US8841429B2 (en) * 2009-11-03 2014-09-23 Vivonics, Inc. Nucleic acid ligands against infectious prions
SI2536748T1 (sl) 2010-02-18 2014-12-31 Genentech, Inc. Nevrogulinski antagonisti in njihova uporaba pri zdravljenju raka
US20140148503A1 (en) * 2011-07-20 2014-05-29 University Of Iowa Research Foundation Nucleic acid aptamers
AU2012312515A1 (en) 2011-09-19 2014-03-13 Genentech, Inc. Combination treatments comprising c-met antagonists and B-raf antagonists
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP2017516458A (ja) 2014-03-24 2017-06-22 ジェネンテック， インコーポレイテッド ｃ−ｍｅｔ拮抗剤による癌治療及びｃ−ｍｅｔ拮抗剤のＨＧＦ発現との相関
AP2016009549A0 (en) 2014-04-18 2016-11-30 Acceleron Pharma Inc Methods for increasing red blood cell levels and treating sickle-cell disease
EP3154566B1 (de) 2014-06-13 2022-08-03 Acceleron Pharma Inc. Actrii antagonist zur behandlung oder prävention eines hautulzers in einem patienten mit anämie
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
MA54328A (fr) 2015-04-06 2021-10-06 Acceleron Pharma Inc Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations
EP3331550B1 (de) 2015-08-04 2022-11-02 Acceleron Pharma Inc. Zusammensetzung zur behandlung von myeloproliferativen erkrankungen
EP3370754A4 (de) 2015-11-04 2019-10-23 Acceleron Pharma Inc. Verfahren zur erhöhung der erythrozytenkonzentration und behandlung von ineffizienter erythropoiese
KR20180096645A (ko) 2015-11-23 2018-08-29 악셀레론 파마 인코포레이티드 눈 질환의 치료 방법
SI3496739T1 (sl) 2016-07-15 2021-06-30 Acceleron Pharma Inc. Sestave, ki zajemajo polipeptide actriia, za uporabo pri zdravljenju pljučne hipertenzije
FI3490582T3 (fi) 2016-07-27 2024-08-01 Acceleron Pharma Inc Koostumuksia käytettäväksi myelofibroosin hoitamisessa
CA3039074A1 (en) 2016-10-05 2018-04-12 Acceleron Pharma Inc. Compositions and method for treating kidney disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3590766T (de) * 1985-03-30 1987-04-23
US5731424A (en) * 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US5472841A (en) * 1990-06-11 1995-12-05 Nexstar Pharmaceuticals, Inc. Methods for identifying nucleic acid ligands of human neutrophil elastase
US5837834A (en) * 1990-06-11 1998-11-17 Nexstar Pharmaceuticals, Inc. High affinity HKGF nucleic acid ligands and inhibitors
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US6270472B1 (en) * 1998-12-29 2001-08-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Apparatus and a method for automatically introducing implants into soft tissue with adjustable spacing
US20020165188A1 (en) * 1999-10-14 2002-11-07 Meenhard Herlyn Methods for inhibition of tumorigenic properties of melanoma cells

Also Published As

Publication number Publication date
US20090075922A1 (en) 2009-03-19
ATE428719T1 (de) 2009-05-15
US20060148748A1 (en) 2006-07-06
US20030049644A1 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
DE60042021D1 (de) Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors
Streit et al. A role for HGF/SF in neural induction and its expression in Hensen’s node during gastrulation
CU23344A3 (es) Azabicicloalcanos como moduladores de ccr5
Melamed et al. A functional B cell receptor transgene allows efficient IL-7-independent maturation of B cell precursors.
DE69635671D1 (de) Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren
ATE517638T1 (de) Verfahren und zubereitungen zum verabreichen von therapeutischen und diagnostischen mitteln
DE69941429D1 (de) 1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a
DE3483085D1 (de) Desulfatohirudine, verfahren zu ihrer herstellung und pharmazeutische mittel.
ATE319440T1 (de) Antidiabetische mittel
PA8429901A1 (es) Compuestos antipicornavirales y metodos para su uso y preparacion
McKinney-Freeman et al. Altered phenotype and reduced function of muscle-derived hematopoietic stem cells
BR0010702A (pt) Novas quinonas como terapias de doenças
Aleksandrova et al. Behavior of human neural progenitor cells transplanted to rat brain
Jiang et al. Hematopoietic stem cells in neural-crest derived bone marrow
EA200200625A1 (ru) Антипикорнавирусные соединения и композиции, их фармацевтическое применение и вещества для их синтеза
DK0952772T3 (da) Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration
ES2039408T3 (es) Un procedimiento para preparar un compuesto de tienotriazolodiazepina.
Geisert et al. Maternal recognition of pregnancy in the pig: A servomechanism involving sex steroids, cytokines and prostaglandins
SE8401125D0 (sv) Sett vid diagnostisering in vitro och diagnostiskt medel
Chen et al. A possible contribution of retinoids to regulation of fetal B lymphopoiesis
ATE375389T1 (de) Verfahren zur diagnose, prognose und behandlung von glaukom und verwandten erkrankungen
Melamed et al. Modulation of matrix metalloproteinase-9 (MMP-9) secretion in B lymphopoiesis
Almotiri et al. Zeb1 maintains long-term adult hematopoietic stem cell function and extramedullary hematopoiesis
DE60130775D1 (de) Stimulierung der neutrophilfunktion zur behandlung von entzündlichen darmerkrankungen
ES2061558T3 (es) Sondas de hibridacion de acidos nucleicos de papilomavirus humanos y metodos para su empleo.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition